NO983003L - Vitronectin-reseptor-antagonister - Google Patents

Vitronectin-reseptor-antagonister

Info

Publication number
NO983003L
NO983003L NO983003A NO983003A NO983003L NO 983003 L NO983003 L NO 983003L NO 983003 A NO983003 A NO 983003A NO 983003 A NO983003 A NO 983003A NO 983003 L NO983003 L NO 983003L
Authority
NO
Norway
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
osteoporosis
compounds
Prior art date
Application number
NO983003A
Other languages
English (en)
Other versions
NO983003D0 (no
Inventor
William Henry Miller
William Edward Bondinell
Thomas Wen-Fu Ku
Richard Mcculloch Keenan
James Martin Samanen
Chet Kwon
Fadia El-Fehail Ali
Maria A Lago
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO983003D0 publication Critical patent/NO983003D0/no
Publication of NO983003L publication Critical patent/NO983003L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Forbindelser med formel I-V er beskrevet og som er vitronectinreseptor- antagonister og kan brukes ved behandlingen av osteoporose.
NO983003A 1995-12-29 1998-06-26 Vitronectin-reseptor-antagonister NO983003L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US936695P 1995-12-29 1995-12-29
PCT/US1996/020748 WO1997024119A1 (en) 1995-12-29 1996-12-20 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
NO983003D0 NO983003D0 (no) 1998-06-26
NO983003L true NO983003L (no) 1998-08-26

Family

ID=21737205

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983003A NO983003L (no) 1995-12-29 1998-06-26 Vitronectin-reseptor-antagonister

Country Status (16)

Country Link
EP (1) EP0869787A4 (no)
JP (1) JP2000502354A (no)
KR (1) KR19990076878A (no)
CN (1) CN1209744A (no)
AU (1) AU1354097A (no)
BR (1) BR9612327A (no)
CA (1) CA2241633A1 (no)
CZ (1) CZ203698A3 (no)
HU (1) HUP9900754A3 (no)
IL (1) IL125033A0 (no)
MX (1) MX9805255A (no)
NO (1) NO983003L (no)
PL (1) PL327694A1 (no)
TR (1) TR199801253T2 (no)
WO (1) WO1997024119A1 (no)
ZA (1) ZA9610859B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6218387B1 (en) * 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
AU8689798A (en) * 1997-08-04 1999-02-22 Smithkline Beecham Corporation Integrin receptor antagonists
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AU759449C (en) 1998-04-09 2003-10-30 Meiji Seika Pharma Co.,Ltd. Aminopiperidine derivatives as integrin alpha v beta 3 antagonists
JP2003523921A (ja) 1998-06-12 2003-08-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
SE9803518D0 (sv) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
WO2000046215A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
EP1165557B1 (en) * 1999-04-02 2004-09-29 Neurogen Corporation ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
AU6360200A (en) 1999-07-21 2001-02-13 American Home Products Corporation Bicyclic antagonists selective for the alphavbeta3 integrin
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
WO2001010867A1 (en) * 1999-08-06 2001-02-15 Smithkline Beecham Corporation Vitronectin receptor antagonists useful for the treatment of strokes
US6509366B2 (en) 2000-01-18 2003-01-21 Neurogen Corporation Substituted imidazoles as selective modulators of Bradykinin B2 receptors
US6545029B2 (en) 2000-06-12 2003-04-08 Bayer Aktiengesellschaft Phenylserine derivatives as integrin antagonists
AR035040A1 (es) 2000-08-01 2004-04-14 Sod Conseils Rech Applic Derivados de imidazolilo, composiciones farmaceuticas que los comprenden y el uso de los mismos para la preparacion de medicamentos capaces de unir selectivamente a los subtipos del receptor de somatostatina
CZ20033119A3 (cs) 2001-04-24 2005-01-12 Merck Patent Gmbh Kombinovaná terapie za použití antiangiogenových činidel a TNF alfa
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
MXPA05012460A (es) * 2003-05-19 2006-05-25 Irm Llc Compuestos y composiciones inmunosupresoras.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2005230846A1 (en) 2004-03-31 2005-10-20 Lexicon Pharmaceuticals, Inc. 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
SG155222A1 (en) 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
EA017249B8 (ru) 2007-05-10 2013-01-30 Олбани Молекьюлар Рисерч, Инк. Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CA3076476A1 (en) 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
WO2019087214A1 (en) 2017-11-06 2019-05-09 Jubilant Biosys Limited Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
PL3704120T3 (pl) 2017-11-24 2024-09-16 Jubilant Episcribe Llc Związki heterocykliczne jako inhibitory prmt5
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627754A (en) * 1970-05-13 1971-12-14 Hoffmann La Roche Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor

Also Published As

Publication number Publication date
WO1997024119A1 (en) 1997-07-10
EP0869787A1 (en) 1998-10-14
HUP9900754A2 (hu) 1999-07-28
CA2241633A1 (en) 1997-07-10
KR19990076878A (ko) 1999-10-25
TR199801253T2 (xx) 1998-12-21
BR9612327A (pt) 1999-07-13
CZ203698A3 (cs) 1999-05-12
PL327694A1 (en) 1998-12-21
EP0869787A4 (en) 1999-03-24
NO983003D0 (no) 1998-06-26
JP2000502354A (ja) 2000-02-29
ZA9610859B (en) 1997-10-24
MX9805255A (es) 1998-11-29
HUP9900754A3 (en) 1999-11-29
AU1354097A (en) 1997-07-28
IL125033A0 (en) 1999-01-26
CN1209744A (zh) 1999-03-03

Similar Documents

Publication Publication Date Title
NO983003L (no) Vitronectin-reseptor-antagonister
NO983002L (no) Vitronectin-reseptor-antagonister
GB9514473D0 (en) Chemical compounds
PT100300B (pt) Derivados de aminas heterociclicas-ciclicas, nomeadamente derivados de benzisoxazole-piperidina
DK0531410T3 (da) (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol
FI973292A7 (fi) Substituoituja isoksatsoleja tulehduksen hoitamiseksi
NO20020567D0 (no) Fremgangsmåte for tillaging og bruk av ozonanriket vann
IT1296619B1 (it) Procedimento per il trattamento di protesi a struttura aperturata e relativi dispositivi.
NO953443D0 (no) Fremgangsmåte for behandling av fast avfall
FI972919A7 (fi) Indolijohdannaisia jotka ovat käyttökelpoisia osteoporoosin hoidossa
SE9802937D0 (sv) Novel compounds
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
NO992504L (no) Sammensetninger for behandling av jord, fremgangsmÕte for fremstilling derav, samt anvendelse
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO913661L (no) Anordning og fremgangsmaate for dosering av vaskemiddelkompositter.
NO20005386D0 (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
ATE300531T1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
EP0618062A3 (de) Sanitärgegenstand, wie Duschtasse oder Badewanne, sowie Verfahren und Vorrichtung zur Herstellung derselben.
ATA93695A (de) Mittel zur behandlung von strahlenschäden
ITRM940140A0 (it) Procedimento e dispositivo per la produzione di potassa.
NO985558D0 (no) Ny forbedret formulering for behandling av tromboembolisme
ITMI911253A0 (it) Macchina per il trattamento e l'erogazione di impasti cementizi, particolarmente per la realizzazione di intonaci
IT1288184B1 (it) Procedimento per l'accorciamento del tempo di chiusura e dispositivo per l'attuazione del procedimento.
ITTO950417A0 (it) Procedimento ed impianto per il trattamento di rifiuti.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application